This article has been updated to reflect the approval of Simlandi (Teva, adalimumab-ryvk)
Bonnie Kirschenbaum, MS, FASHP, FCSHP
“Reimbursement Matters” is a tool for maintaining your health system’s fiscal health. Please email the author at bonniekirschenbaum@gmail.com with suggestions on reimbursement issues that you would like to see covered.
This month’s column primarily covers two major issues confronting pharmacy: prior authorization (PA) and the deluge